Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

STATs in cancer inflammation and immunity: a leading role for STAT3

Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · see citing works

STATs and Gene Regulation

Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979 · see citing works

Revisiting STAT3 signalling in cancer: new and unexpected biological functions

Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137 · see citing works

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,074 · see citing works

Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue

Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790 · see citing works

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B. M., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 734 · see citing works

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731 · see citing works

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652 · see citing works

Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB

Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., & Stark, G. R. (2007) · Genes & Development · doi:10.1101/gad.1553707 · Cited by 611 · see citing works

Targeted protein degradation by PROTACs

Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599 · see citing works

JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance

Wang, T., Fahrmann, J., Lee, H., Li, Y.-J., Tripathi, S. C., Yue, C., Zhang, C.-Y., Lifshitz, V., Song, J., Yuan, Y., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.001 · Cited by 580 · see citing works

A Review on Anti-Inflammatory Activity of Monoterpenes

Sá, R. D. C. D. S. E., Andrade, L., & de Sousa, D. P. (2013) · Molecules · doi:10.3390/molecules18011227 · Cited by 558 · see citing works

Terpenes: substances useful in human healthcare

Paduch, R., Kandefer‐Szerszeń, M., Trytek, M., & Fiedurek, J. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0039-1 · Cited by 452 · see citing works

STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review

Qin, J., Li, Y., Zhang, J., & Zhang, W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 407 · see citing works

Strategies and Approaches of Targeting STAT3 for Cancer Treatment

Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 348 · see citing works

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W. M., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 347 · see citing works

First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313 · see citing works

The biology of Stat4 and Stat6

Wurster, A. L., Tanaka, T., & Grusby, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203485 · Cited by 309 · see citing works

Activation of Stat3 Sequence-specific DNA Binding and Transcription by p300/CREB-binding Protein-mediated Acetylation

Wang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275 · see citing works

Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update

Dong, J., Qin, Z., Zhang, W., Cheng, G., Assaraf, Y. G., Ashby, C. R., Chen, Z., Cheng, X., & Qin, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 259 · see citing works

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor

Redell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B., & Tweardy, D. J. (2011) · Blood · doi:10.1182/blood-2010-04-280123 · Cited by 258 · see citing works

Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein

Turkson, J., Bowman, T. L., Adnane, J., Zhang, Y., Djeu, J. Y., Sekharam, M., Frank, D. A., Holzman, L. B., Wu, J., Sebti, S. M., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7519 · Cited by 256 · see citing works

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer

Wingelhofer, B., Neubauer, H. A., Valent, P., Han, X., Constantinescu, S. N., Gunning, P. T., Müller, M. M., & Moriggl, R. (2018) · Leukemia · doi:10.1038/s41375-018-0117-x · Cited by 245 · see citing works

Activation of STAT3 is a marker of poor prognosis in human colorectal cancer

Kusaba, T., Nakayama, T., Yamazumi, K., Yakata, Y., Yoshizaki, A., Inoue, K., Nagayasu, T., & Sekine, I. (2006) · Oncology Reports · doi:10.3892/or.15.6.1445 · Cited by 238 · see citing works

Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation

Lee, H., Zhang, P., Herrmann, A., Yang, C., Xin, H., Wang, Z., Hoon, D. S. �., Forman, S. J., Jove, R., Riggs, A. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205132109 · Cited by 235 · see citing works

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233 · see citing works

Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F. A., Gattenlöhner, S., Meinhold-Heerlein, I. M., & Hussain, A. F. (2019) · Cancers · doi:10.3390/cancers11121826 · Cited by 223 · see citing works

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Röhrig, U. F., Majjigapu, S. R., Vogel, P., Zoete, V., & Michielin, O. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00326 · Cited by 206 · see citing works

Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein

Debnath, B., Xu, S., & Neamati, N. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300207s · Cited by 205 · see citing works

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

Wang, X., Crowe, P. J., Goldstein, D., & Yang, J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1568 · Cited by 202 · see citing works

Regulation of STAT signaling by acetylation

Zhuang, S. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.007 · Cited by 199 · see citing works

Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment

Zhuang, C., Guan, X., Ma, H., Cong, H., Zhang, W., & Miao, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.035 · Cited by 188 · see citing works

A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes

Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179 · see citing works

Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development

Sgrignani, J., Garofalo, M., Matkovic, M., Merulla, J., Catapano, C. V., & Cavalli, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061591 · Cited by 166 · see citing works

Napabucasin: an update on the first-in-class cancer stemness inhibitor

Hubbard, J. M., & Grothey, A. (2017) · Drugs · doi:10.1007/s40265-017-0759-4 · Cited by 157 · see citing works

STAT3 in cancer: A double edged sword

Avalle, L., Camporeale, A., Camperi, A., & Poli, V. (2017) · Cytokine · doi:10.1016/j.cyto.2017.03.018 · Cited by 156 · see citing works

A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells

Lin, L., Deangelis, S., Foust, E., Fuchs, J. R., Li, C., Li, P., Schwartz, E. B., Lesinski, G. B., Benson, D., Lü, J., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-217 · Cited by 149 · see citing works

Identification of a New Series of STAT3 Inhibitors by Virtual Screening

Matsuno, K., Masuda, Y., Uehara, Y., Satō, H., Muroya, A., Takahashi, O., Yokotagawa, T., Furuya, T., Okawara, T., Otsuka, M., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000273 · Cited by 147 · see citing works

Mitochondrial Stat3, the need for design thinking

Yang, R., & Rincon, M. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15153 · Cited by 147 · see citing works

Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma

Cao, H., Chu, J., Kwan, H. Y., Su, T., Yu, H., Cheng, C.-Y., Fu, X., Guo, H., Li, T., Tse, A. K., et al. (2016) · Scientific Reports · doi:10.1038/srep21731 · Cited by 146 · see citing works

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

Takakura, A., Nelson, E. A., Haque, N., Humphreys, B. D., Zandi-Nejad, K., Frank, D. A., & Zhou, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr338 · Cited by 143 · see citing works

Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

Beebe, J., Liu, J., & Zhang, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.006 · Cited by 142 · see citing works

Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases.

Lee, J. H., Chiang, S.-Y., Nam, D., Chung, W., Lee, J., Na, Y., Sethi, G., & Ahn, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.12.008 · Cited by 135 · see citing works

Mechanisms of Unphosphorylated STAT3 Transcription Factor Binding to DNA

Timofeeva, O. A., Chasovskikh, S., Lonskaya, I., Tarasova, N. I., Khavrutskii, L., Tarasov, S. G., Zhang, X., Korostyshevskiy, V. R., Cheema, A. K., Zhang, L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323899 · Cited by 134 · see citing works

Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors

Lee, Y. G., Marks, I. S., Srinivasarao, M., Kanduluru, A. K., Mahalingam, S. M., Liu, X., Chu, H., & Low, P. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1834 · Cited by 132 · see citing works

Negative Regulation of STAT3 Protein-mediated Cellular Respiration by SIRT1 Protein

Bernier, M., Paul, R. K., Martín‐Montalvo, A., Scheibye‐Knudsen, M., Song, S., He, H., Armour, S. M., Hubbard, B. P., Bohr, V. A., Wang, L., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.200311 · Cited by 127 · see citing works

Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma

Haftchenary, S., Luchman, H. A., Jouk, A. O., Veloso, A. J., Page, B. D. G., Cheng, X. R., Dawson, S. S., Grinshtein, N., Shahani, V. M., Kerman, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4003138 · Cited by 126 · see citing works

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies

Arora, L., Kumar, A. P., Arfuso, F., Chng, W. J., & Sethi, G. (2018) · Cancers · doi:10.3390/cancers10090327 · Cited by 124 · see citing works

A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion

Huang, W., Dong, Z., Wang, F., Peng, H., Liu, J., & Zhang, J. (2014) · ACS Chemical Biology · doi:10.1021/cb500071v · Cited by 123 · see citing works

Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents

Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003082 · Cited by 121 · see citing works

Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility

Ding, C., Zhang, Y., Chen, H., Yang, Z., Wild, C., Chu, L., Liu, H., Shen, Q., & Zhou, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400367n · Cited by 114 · see citing works

Identifying and targeting cancer stem cells in the treatment of gastric cancer

Bekaii‐Saab, T., & El‐Rayes, B. F. (2017) · Cancer · doi:10.1002/cncr.30538 · Cited by 112 · see citing works

Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo

Huang, W., Dong, Z., Chen, Y., Wang, F., Wang, C. J., Peng, H., He, Y., Hangoc, G., Pollok, K. E., Sandusky, G. E., et al. (2015) · Oncogene · doi:10.1038/onc.2015.215 · Cited by 110 · see citing works

A Novel Sequence in the Coiled-coil Domain of Stat3 Essential for Its Nuclear Translocation

Ma, J., Zhang, T., Novotny-Diermayr, V., Tan, A. L. C., & Cao, X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304196200 · Cited by 110 · see citing works

Emerging molecular targets in melanoma invasion and metastasis

Orgaz, J. L., & Sanz‐Moreno, V. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12041 · Cited by 109 · see citing works

Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Xiang, M. H., Kim, H. T., Ho, V. T., Walker, S. R., Bar‐Natan, M., Anahtar, M., Liu, S., Toniolo, P. A., Kroll, Y., Jones, N., et al. (2016) · Blood · doi:10.1182/blood-2015-07-660506 · Cited by 109 · see citing works

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma

Ashizawa, T., Miyata, H., Iizuka, A., Komiyama, M., Oshita, C., KUME, A., Nogami, M., Yagoto, M., Ito, I., Oishi, T., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1916 · Cited by 101 · see citing works

Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity

Page, B. D. G., Khoury, H., Laister, R. C., Fletcher, S., Vellozo, M., Manzoli, A., Yue, P., Turkson, J., Minden, M. D., & Gunning, P. T. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200720n · Cited by 99 · see citing works

The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma

Liu, Y., Wang, X., Zeng, S., Zhang, X., Zhao, J., Zhang, X., Chen, X., Yang, W., Yang, Y., Dong, Z., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0959-0 · Cited by 99 · see citing works

Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer

Mali, S. B. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.03.004 · Cited by 96 · see citing works

Hitting the right spot: Mechanism of action of OPB‐31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)

Brambilla, L., Genini, D., Laurini, E., Merulla, J., Perez, L. H., Fermeglia, M., Carbone, G. M., Pricl, S., & Catapano, C. V. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.012 · Cited by 95 · see citing works

Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells

Don‐Doncow, N., Escobar, Z., Johansson, M., Kjellström, S., Garcia, V., Muñóz, E., Sterner, O., Bjartell, A. S., & Hellsten, R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564252 · Cited by 94 · see citing works

Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?

Huang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., Qu, X., Hu, W., Zhang, X., & Wang, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111922 · Cited by 93 · see citing works

Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3–COX2-dependent pathway

Li, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 91 · see citing works

The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation

Boengler, K., Ungefug, E., Heusch, G., & Schulz, R. (2013) · Current Pharmaceutical Design · doi:10.2174/138161281939131127115940 · Cited by 89 · see citing works

Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells

Hahn, Y., Kim, S., Choi, B., Cho, K.-C., Bandu, R., Kim, K. P., Kim, D., Kim, W.-K., Park, J. S., Han, B. W., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23840-2 · Cited by 88 · see citing works

Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade

Jung, Y. Y., Lee, J. H., Nam, D., Narula, A. S., Namjoshi, O. A., Blough, B. E., Um, J., Sethi, G., & Ahn, K. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00531 · Cited by 84 · see citing works

Targeting colon cancer with the novel STAT3 inhibitor bruceantinol

Wei, N., Li, J., Fang, C., Chang, J., Xirou, V., Syrigos, N. K., Marks, B. J., Chu, E., & Schmitz, J. C. (2018) · Oncogene · doi:10.1038/s41388-018-0547-y · Cited by 84 · see citing works

Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway

Xu, Y., Xu, X., Gao, X., Chen, H., & Geng, L. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.01.027 · Cited by 83 · see citing works

Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization

Jamroškovič, J., Doimo, M., Chand, K., Obi, I. R., Kumar, R., Brännström, K., Hedenström, M., Das, R. N., Akhunzianov, A., Deiana, M., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11232 · Cited by 80 · see citing works

Osthole inhibits triple negative breast cancer cells by suppressing STAT3

Dai, X.-X., Yin, C.-T., Zhang, Y., Guo, G., Zhao, C.-G., Wang, O.-C., Xiang, Y.-Q., Zhang, X.-H., & Liang, G. (2018) · Journal of experimental & clinical cancer research : CR · doi:10.1186/s13046-018-0992-z · Cited by 79 · see citing works

Signal Transducer and Activator of Transcription 3 (STAT3): A Promising Target for Anticancer Therapy

Masciocchi, D., Gelain, A., Villa, S., Meneghetti, F., & Barlocco, D. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.22 · Cited by 78 · see citing works

Silibinin is a direct inhibitor of STAT3

Verdura, S., Cuyàs, E., Llorach-Parés, L., Pérez-Sánchez, A., Micol, V., Nonell‐Canals, A., Joven, J., Valiente, M., Sánchez-Martínez, M., Bosch‐Barrera, J., et al. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.04.028 · Cited by 78 · see citing works

An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-κB

Kang, T., Wang, W., Zhong, H., Dong, Z., Huang, Q., Mok, S. W. F., Leung, C., Wong, V. K. W., & Ma, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.016 · Cited by 77 · see citing works

Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells

Chen, W., Li, P., Liu, Y., Yu, Y., Ye, X., Zhang, F., & Huang, H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0987-9 · Cited by 77 · see citing works

Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors

Mankan, A. K., & Greten, F. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601739 · Cited by 75 · see citing works

Observation of unphosphorylated STAT3 core protein binding to target ds DNA by PEMSA and X‐ray crystallography

Nkansah, E., Shah, R., Collie, G. W., Parkinson, G. N., Palmer, J. M., Rahman, K. M., Bui, T. T. T., Drake, A. F., Husby, J., Neidle, S., et al. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.01.065 · Cited by 75 · see citing works

Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors

Cai, G., Yu, W., Song, D., Zhang, W., Guo, J., Zhu, J., Ren, Y., & Kong, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.024 · Cited by 75 · see citing works

Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling

Kwon, G. T., Jung, J. I., Song, H. R., Woo, E. Y., Jun, J., Kim, J., Her, S., & Park, J. H. Y. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.11.019 · Cited by 73 · see citing works

Hydroxamic Acid and Benzoic Acid–Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo

Yue, P., Lopez‐Tapia, F., Paladino, D., Li, Y., Chen, C., Namanja, A. T., Hilliard, T. S., Chen, Y., Tius, M. A., & Turkson, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3558 · Cited by 72 · see citing works

Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells

Löcken, H., Clamor, C., & Müller, K. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00247 · Cited by 71 · see citing works

Suppressive Effects of Plumbagin on Invasion and Migration of Breast Cancer Cells via the Inhibition of STAT3 Signaling and Down-regulation of Inflammatory Cytokine Expressions

Yan, W., Tu, B., Liu, Y., Wang, T., Qiao, H., Zhai, Z., Li, H., & Tang, T. (2013) · Bone Research · doi:10.4248/br201304007 · Cited by 68 · see citing works

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition

Selvendiran, K., Ahmed, S., Dayton, A., Kuppusamy, M. L., Rivera, B. K., Kálai, T., Hideg, K., & Kuppusamy, P. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17713 · Cited by 68 · see citing works

STAT2 phosphorylation and signaling

Steen, H. C., & Gamero, A. M. (2013) · JAK-STAT · doi:10.4161/jkst.25790 · Cited by 67 · see citing works

Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate

Muller, A. J., DuHadaway, J. B., Jaller, D., Curtis, P. J., Metz, R. A., & Prendergast, G. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3613 · Cited by 64 · see citing works

Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91

Hanafi, M., Chen, X., & Neamati, N. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01897 · Cited by 61 · see citing works

Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity

Hu, T., Yeh, J. E., Pinello, L., Jacob, J., Chakravarthy, S., Yuan, G.-C., Chopra, R., & Frank, D. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00060-15 · Cited by 60 · see citing works

A STAT inhibitor patent review: progress since 2011

Lai, P., Rosa, D. A., Ali, A. M., Gómez‐Biagi, R. F., Ball, D. P., Shouksmith, A. E., & Gunning, P. T. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1086749 · Cited by 59 · see citing works

Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity

Mertens, C., Haripal, B., Klinge, S., & Darnell, J. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515876112 · Cited by 59 · see citing works

Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development

Buettner, R., Corzano, R., Rashid, R., Lin, J., Senthil, M., Hedvat, M., Schroeder, A., Mao, A., Herrmann, A., Yim, J. H., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb100253e · Cited by 58 · see citing works

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 56 · see citing works

STAT3 transcription factor as target for anti-cancer therapy

Mohassab, A. M., Hassan, H. A., Abdelhamid, D. S., & Abdel‐Aziz, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00156-5 · Cited by 54 · see citing works

Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules

Fletcher, S., Page, B. D. G., Zhang, X., Yue, P., Li, Z. H., Sharmeen, S., Singh, J., Zhao, W. M., Schimmer, A. D., Trudel, S., et al. (2011) · ChemMedChem · doi:10.1002/cmdc.201100194 · Cited by 52 · see citing works

Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents

Gelain, A., Mori, M., Meneghetti, F., & Villa, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719122729 · Cited by 49 · see citing works

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking

Yu, W., Li, C., Zhang, W., Xia, Y., Li, S., Lin, J., Yu, K., Liu, M., Yang, L. F., Luo, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01489 · Cited by 48 · see citing works

Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3

Huang, R.-Z., Jing, X.-T., Huang, X., Pan, Y.-M., Fang, Y., Liang, G.-B., Liao, Z., Wang, H., Chen, Z., & Zhang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01386 · Cited by 48 · see citing works

Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules

Zhang, W., Ma, T., Li, S., Yang, Y., Guo, J., Yu, W., & Kong, L. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.068 · Cited by 46 · see citing works

A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)

Li, C., Chen, C., An, Q., Yang, T., Sang, Z., Yang, Y., Ju, Y., Tong, A., & Luo, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.067 · Cited by 46 · see citing works

Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis

Huang, W., Liu, Y., Wang, J., Yuan, X., Jin, H.-W., Zhang, L.-R., Zhang, J., Liu, Z.-M., & Cui, J.-R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.037 · Cited by 45 · see citing works

UPLC/MS/MS method for quantification and cytotoxic activity of sesquiterpene lactones isolated from Saussurea lappa

Kumar, A., Kumar, S., Kumar, D., & Agnihotri, V. K. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.07.037 · Cited by 45 · see citing works

Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors

Brotherton‐Pleiss, C., Yue, P., Zhu, Y., Nakamura, K., Chen, W., Fu, W., Kubota, C. S., Chen, J., Alonso-Valenteen, F., Mikhael, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01705 · Cited by 43 · see citing works

Design, synthesis and activity of BBI608 derivatives targeting on stem cells

Zhou, Q., Peng, C., Du, F., Zhou, L., Shi, Y., Du, Y., Liu, D., Sun, W., Zhang, M., & Chen, G. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.054 · Cited by 43 · see citing works

Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells

Lu, Z., Zhang, G., Zhang, Y., Hua, P., Fang, M.-D., Wu, M., & Liu, T. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.026 · Cited by 43 · see citing works

Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors

Dong, J., Wang, Z., Cui, J., Meng, Q., & Li, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111938 · Cited by 43 · see citing works

STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model

Kim, B., Lee, H., Park, C. G., Jeong, A. J., Lee, S. H., Noh, K. H., Park, J. B., Lee, C.-G., Paek, S. H., Kim, H., et al. (2020) · Cells · doi:10.3390/cells9030722 · Cited by 42 · see citing works

An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties

Porta, F., Facchetti, G., Ferri, N., Gelain, A., Meneghetti, F., Villa, S., Barlocco, D., Masciocchi, D., Asai, A., Miyoshi, N., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.017 · Cited by 41 · see citing works

Identification of new shikonin derivatives as STAT3 inhibitors

Qiu, H., Fu, J., Yang, M., Han, H., Wang, P., Zhang, Y., Lin, H., Tang, C., Qi, J., Yang, R., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.009 · Cited by 40 · see citing works

Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains

Shih, P. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117241 · Cited by 40 · see citing works

JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells.

Nishimoto, A., Kugimiya, N., Hosoyama, T., Enoki, T., Li, T.-S., & Hamano, K. (2013) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2013.07.105 · Cited by 39 · see citing works

Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells

Mantaj, J., Rahman, S. M. A., Bokshi, B., Hasan, C. M., Jackson, P. J., Parsons, R. B., & Rahman, K. M. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00052a · Cited by 39 · see citing works

Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy

Zhang, W., Guo, J., Li, S., Ma, T., Xu, D., Han, C., Liu, F., Yu, W., & Kong, L. (2017) · Scientific Reports · doi:10.1038/srep46352 · Cited by 39 · see citing works

MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain

Son, D. J., Zheng, J., Jung, Y. Y., Hwang, C. J., Lee, H. P., Woo, J. R., Baek, S. Y., Ham, Y. W., Kang, M. W., Shong, M., et al. (2017) · Theranostics · doi:10.7150/thno.18630 · Cited by 39 · see citing works

Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma

Page, B. D. G., Croucher, D. C., Li, Z., Haftchenary, S., Jimenez-Zepeda, V. H., Atkinson, J. M., Spagnuolo, P. A., Wong, Y. L., Colaguori, R., Lewis, A. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017255 · Cited by 38 · see citing works

Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line

Ashizawa, T., Akiyama, Y., Miyata, H., Iizuka, A., Komiyama, M., Kume, A., Omiya, M., Sugino, T., Asai, A., Hayashi, N., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2439 · Cited by 38 · see citing works

Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity

Minus, M. B., Liu, W., Vohidov, F., Kasembeli, M. M., Long, X., Krueger, M. J., Stevens, A., Kolosov, M. I., Tweardy, D. J., Sison, E. A. R., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506889 · Cited by 38 · see citing works

Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors

Pallandre, J., Borg, C., Rognan, D., Boibessot, T., Luzet, V., Yesylevskyy, S. O., Ramseyer, C., & Pudlo, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.054 · Cited by 37 · see citing works

Blockage of STAT3 Signaling Pathway by Morusin Induces Apoptosis and Inhibits Invasion in Human Pancreatic Tumor Cells

Kim, C., Kim, J. H., Oh, E., Nam, D., Lee, S.-G., Lee, J., Kim, S.-H., Shim, B., & Ahn, K. (2016) · Pancreas · doi:10.1097/mpa.0000000000000496 · Cited by 37 · see citing works

Preclinical Characterization of 3β-(N-Acetyl l -cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer

Escobar, Z., Bjartell, A. S., Canesin, G., Axelsson, S. E., Sterner, O., Hellsten, R., & Johansson, M. H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01814 · Cited by 37 · see citing works

Aspeterreurone A, a Cytotoxic Dihydrobenzofuran–Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18

Wang, W., Yang, J., Liao, Y., Cheng, G., Chen, J., Mo, S., Li, Y., Cheng, X., Qin, J., & Shao, Z. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00189 · Cited by 36 · see citing works

GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling

Kou, X., Chen, N., Feng, Z., Luo, L., & Yin, Z. (2012) · Oncology Letters · doi:10.3892/ol.2012.1098 · Cited by 35 · see citing works

Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain

Qiu, H., Zhu, X., Luo, Y., Lin, H., Tang, C., Qi, J., Pang, Y.-J., Yang, R., Lu, G., Wang, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02671-7 · Cited by 35 · see citing works

NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth

Kaoud, T. S., Mohassab, A. M., Hassan, H. A., Yan, C., Ravenstein, S. X. V., Abdelhamid, D. S., Dalby, K. N., & Abdel‐Aziz, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111885 · Cited by 34 · see citing works

2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors

Lamie, P. F., & Philoppes, J. N. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1740922 · Cited by 34 · see citing works

A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3

Shen, X., Zhao, L., Chen, P., Gong, Y., Liu, D., Zhang, X., Dai, L., Sun, Q., Lou, J., Jin, Z., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009801 · Cited by 34 · see citing works

Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors

Dong, J., Huang, G., Cui, Q., Meng, Q., Li, S., & Cui, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112895 · Cited by 34 · see citing works

Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase

Jin, Y., Yoon, Y. J., Jeon, Y. J., Choi, J., Lee, Y.-J., Lee, J., Choi, S., Nash, O., Han, D. C., & Kwon, B. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.131 · Cited by 33 · see citing works

Allosteric inhibitors of the STAT3 signaling pathway

Qin, J., Shen, X., Zhang, J., & Jia, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112122 · Cited by 33 · see citing works

Inhibition of STAT3 acetylation is associated with attenuated renal fibrosis in the obstructed kidney

Ni, J., Shen, Y., Wang, Z., Shao, D., Liu, J., Fu, L., Kong, Y.-L., Zhou, L., Xue, H., Huang, Y., et al. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.42 · Cited by 33 · see citing works

LL1, a novel and highly selective STAT3 inhibitor, displays anti‐colorectal cancer activities in vitro and in vivo

Liu, Z., Wang, H., Guan, L., Lai, C., Yu, W., & Lai, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14863 · Cited by 32 · see citing works

A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction

Park, S. K., Byun, W. S., Lee, S., Han, Y. T., Jeong, Y., Jang, K., Chung, S., Lee, J., Suh, Y., & Lee, S. K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114053 · Cited by 32 · see citing works

Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors

Gao, D., Jin, N., Fu, Y., Zhu, Y., Wang, Y., Wang, T., Chen, Y., Zhang, M., Xiao, Q., Huang, M., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113333 · Cited by 32 · see citing works

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line

Akiyama, Y., Nonomura, C., Ashizawa, T., Iizuka, A., Kondou, R., Miyata, H., Sugino, T., Mitsuya, K., Hayashi, N., Nakasu, Y., et al. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.07.005 · Cited by 32 · see citing works

C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma

Di, J.-X., & Zhang, H. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000783 · Cited by 32 · see citing works

Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors

LaPorte, M. G., Wang, Z., Colombo, R., Garzan, A., Peshkov, V. A., Liang, M., Johnston, P. A., Schurdak, M. E., Sen, M., Camarco, D. P., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.06.017 · Cited by 31 · see citing works

N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling

Lai, M.-J., Lee, H., Chuang, H., Chang, L., Tsai, A.-C., Chen, M.-C., Huang, H.-L., Wu, Y., Teng, C., Pan, S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00659 · Cited by 30 · see citing works

Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma

Miklóssy, G., Youn, U. J., Yue, P., Zhang, M., Chen, C.-H., Hilliard, T. S., Paladino, D., Li, Y., Choi, J. C.-B., Sarkaria, J. N., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00686 · Cited by 29 · see citing works

Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy

Feng, K.-R., Wang, F., Shi, X., Tan, Y., Zhao, J., Zhang, J., Li, Q., Lin, G., Gao, D., & Tian, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112428 · Cited by 29 · see citing works

Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells

Lis, C., Rubner, S., Roatsch, M., Berg, A., Gilcrest, T., Fu, D., Nguyen, E. D., Schmidt, A.-M., Krautscheid, H., Meiler, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17600-x · Cited by 28 · see citing works

Crispenes F and G, cis-Clerodane Furanoditerpenoids from Tinospora crispa, Inhibit STAT3 Dimerization

Noman, M. A. A., Hossain, T., Ahsan, M., Jamshidi, S., Hasan, C. M., & Rahman, K. M. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00377 · Cited by 27 · see citing works

Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents

Dong, J., Huang, G., Zhang, Q., Wang, Z., Cui, J., Wu, Y. F., Meng, Q., & Li, S. (2019) · MedChemComm · doi:10.1039/c9md00258h · Cited by 27 · see citing works

2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling

Yue, Y., Qian, W., Li, J., Wu, S., Zhang, M., Wu, Z., Ma, Q., & Wang, Z. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.041 · Cited by 26 · see citing works

LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis

Wang, H., Liu, Z., Guan, L., Li, J., Chen, S., Yu, W., & Lai, M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104661 · Cited by 25 · see citing works

Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3

Wang, X., He, Q., Wu, K., Guo, T., Du, X., Zhang, H., Fang, L., Zheng, N., Zhang, Q., & Ye, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.017 · Cited by 24 · see citing works

Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors

Chau, M. N., & Banerjee, P. P. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.10.025 · Cited by 22 · see citing works

Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines

Kim, H. S., Kim, T., Ko, H., Lee, J., Kim, Y. S., & Suh, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.036 · Cited by 22 · see citing works

Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo

Liu, Z., Ge, X., Gu, Y., Huang, Y., Liu, H., Yu, M., & Liu, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109502 · Cited by 22 · see citing works

Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons

Pfeffer, S. R., Fan, M., Du, Z., Yang, C. H., & Pfeffer, L. M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.111 · Cited by 21 · see citing works

Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations

Yesylevskyy, S. O., Ramseyer, C., Pudlo, M., Pallandre, J., & Borg, C. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00198 · Cited by 20 · see citing works

Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors

Khanam, R., Hejazi, I. I., Shahabuddin, S., Bhat, A. R., & Athar, F. (2018) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2018.12.002 · Cited by 20 · see citing works

Linker Variation and Structure–Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors

Lopez‐Tapia, F., Brotherton‐Pleiss, C., Yue, P., Murakami, H. A., Araujo, A. C. C., dos Santos, B. R., Ichinotsubo, E., Rabkin, A., Shah, R., Lantz, M. J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00544 · Cited by 19 · see citing works

Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors

Guo, J., Yu, W., Cai, G., Zhang, W., Li, S., Zhu, J., Song, D., & Kong, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.053 · Cited by 19 · see citing works

Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO‐1701

Nishisaka, F., Taniguchi, K., Tsugane, M., Hirata, G., Takagi, A., Asakawa, N., Kurita, A., Takahashi, H., Ogo, N., Shishido, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14369 · Cited by 19 · see citing works

N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin

Zhou, Q., Zhu, J., Chen, J., Ji, P., & Qiao, C. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.023 · Cited by 19 · see citing works

Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy

Kim, B., Lee, H., Song, Y., Park, J.-S., Gadhe, C. G., Choi, J., Lee, C.-G., Pae, A. N., Kim, S., & Ye, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111847 · Cited by 19 · see citing works

Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer

Huang, M., Chen, Z., Zhang, L., Huang, Z., Chen, Y., Xu, J., Zhang, J., & Shu, X. H. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.073 · Cited by 18 · see citing works

Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide

Wang, X., Wu, K., Fang, L., Yang, X., Zheng, N., Du, Z., Lu, Y., Xie, Z., Liu, Z., Zuo, Z., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113362 · Cited by 18 · see citing works

Inhibition of STAT3 by Anticancer Drug Bendamustine

Iwamoto, K., Uehara, Y., Inoue, Y., Taguchi, K., Muraoka, D., Ogo, N., Matsuno, K., & Asai, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170709 · Cited by 17 · see citing works

Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition

Li, N., Ou, J., Bao, N., Cheng, C., Shi, Z., Chen, L., & Sun, J. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104208 · Cited by 17 · see citing works

Shikonin inhibits IFN-γ-induced K17 over-expression of HaCaT cells by interfering with STAT3 signaling.

Liu, L., Wu, Y., Cao, K., Xu, Y.-Y., Gao, X. H., Chen, H. D., & Geng, L. (2015) · PubMed Central · Cited by 15 · see citing works

Identification of small molecule inhibitors of the STAT3 signaling pathway: Insights into their structural features and mode of action

Kim, K., Kim, S., Han, Y. T., Hong, S.-J., An, H., Chang, D., Kim, T., Lim, B., Lee, J., Surh, Y., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.063 · Cited by 15 · see citing works

Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic–inorganic inhibitors

Minus, M. B., Wang, H., Munoz, J. O., Stevens, A. M., Mangubat-Medina, A. E., Krueger, M., Liu, W., Kasembeli, M. M., Cooper, J. C., Kolosov, M. I., et al. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob02682g · Cited by 13 · see citing works

Discovery of a New STAT3 Inhibitor Acting on the Linker Domain

Koseki, T., Suehiro, N., Masuda, Y., Miyoshi, N., Muraoka, D., Ogo, N., & Asai, A. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00992 · Cited by 13 · see citing works

Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines

Taniguchi, K., Konishi, H., Yoshinaga, A., Tsugane, M., Takahashi, H., Nishisaka, F., Shishido, Y., & Asai, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-86021-8 · Cited by 12 · see citing works

Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study

Wang, F., Feng, K., Zhao, J., Zhang, J., Shi, X., Zhou, J. E., Gao, D., Lin, G., & Tian, P. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115822 · Cited by 11 · see citing works

Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2′-Deoxycytidine Against Pancreatic Cancer

Kong, R., Sun, G., Li, X., Wu, L., Li, L., Li, Y., Wang, F., Xuan, P., Yang, S., Sun, B., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00612 · Cited by 11 · see citing works

4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway

Ji, P., Yuan, C., Ma, S., Fan, J., Fu, W., & Qiao, C. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.070 · Cited by 10 · see citing works

Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues

Chen, L., Xie, Y., Luo, Z.-Y., Liu, L., Zou, Z., Liu, H., Kong, F.-R., Hao, Y., Gao, J., Wang, L., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127286 · Cited by 9 · see citing works

Abstract 387: Pyrimethamine inhibits STAT3 transcriptional activity via dihydrofolate reductase

Heppler, L. N., Walker, S. R., Attarha, S., Page, B. D. G., & Frank, D. A. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-387 · Cited by 1 · see citing works

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 491 · see citing works

Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy

Wang, Z., Zhang, Z.-C., Wu, Y., Pi, Y., Lou, S., Liu, T., Lou, G., & Yang, C. Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01647-6 · Cited by 222 · see citing works

Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review

Dong, J., Li, Y., Hu, C., Cheng, X., & Qin, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108488 · Cited by 186 · see citing works

Protein degradation technology: a strategic paradigm shift in drug discovery

Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X., & Qin, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01146-7 · Cited by 94 · see citing works

Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives

Li, Y., Song, J. H., Zhou, P., Zhou, J., & Xie, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00691 · Cited by 88 · see citing works

JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences

Ott, N., Faletti, L. E., Heeg, M., Andreani, V., & Grimbacher, B. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01483-x · Cited by 87 · see citing works

μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping

Huth, S. W., Oakley, J. V., Seath, C. P., Geri, J. B., Trowbridge, A., Parker, D. L., Rodriguez‐Rivera, F. P., Schwaid, A. G., Ramil, C. P., Ryu, K. A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03325 · Cited by 73 · see citing works

PROTACs: A novel strategy for cancer drug discovery and development

Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 67 · see citing works

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 66 · see citing works

JAK2/STAT3 as a new potential target to manage neurodegenerative diseases: An interactive review

Panda, S. P., Kesharwani, A., Datta, S., Prasanth, D., Panda, S. K., & Guru, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176490 · Cited by 60 · see citing works

Integrating Single-Cell and Spatial Transcriptomics to Uncover and Elucidate GP73-Mediated Pro-Angiogenic Regulatory Networks in Hepatocellular Carcinoma

Ye, J., Gao, X., Huang, X., Huang, S., Zeng, D., Luo, W., Zeng, C., Lu, C. C., Lu, L., Huang, H., et al. (2024) · Research · doi:10.34133/research.0387 · Cited by 55 · see citing works

Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives

Song, J., Wang, J., Tian, S., & Li, H. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220819093117 · Cited by 54 · see citing works

DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting

Li, S., Zeng, T., Wu, Z., Huang, J., Cao, X., Liu, Y., Bai, S., Chen, Q., Li, C., Lü, C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c16438 · Cited by 52 · see citing works

Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy

Shi, D., Tao, J., Man, S., Zhang, N., Ma, L., Guo, L., Huang, L., & Gao, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189207 · Cited by 51 · see citing works

Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance

Hashemi, M., Sabouni, E., Rahmanian, P., Entezari, M., Mojtabavi, M., Raei, B., Zandieh, M. A., Behroozaghdam, M., Mirzaei, S., Hushmandi, K., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00438-9 · Cited by 50 · see citing works

Targeting the STAT3 pathway with STAT3 degraders

Wang, Z., Liao, X., He, H., Guo, X., & Chen, J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.07.003 · Cited by 46 · see citing works

Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization

Xuan, C., Chen, D., Zhang, S., Li, C., Fang, Q., Chen, D., Liu, J., Jiang, X., Zhang, Y., Shen, W., et al. (2025) · Advanced Science · doi:10.1002/advs.202414587 · Cited by 49 · see citing works

The role of the STAT3 signaling transduction pathways in radioresistance

Shih, P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108118 · Cited by 43 · see citing works

Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment

Huang, C., Bian, A., Zhou, W., Miao, Y., Ye, J., Li, J., He, P., Zhang, Q., Sun, Y., Sun, Z., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01440 · Cited by 43 · see citing works

Unveiling the potential of isatin-grafted phenyl-1,2,3-triazole derivatives as dual VEGFR-2/STAT-3 inhibitors: Design, synthesis and biological assessments

Elsebaie, H. A., Abdulla, M., Elsayed, Z. M., Shaldam, M. A., Tawfik, H. O., Morsy, S. N., Vaali‐Mohammed, M., Traiki, T. B., Elkaeed, E. B., Abdel‐Aziz, H. A., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107626 · Cited by 42 · see citing works

Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming

Zhou, S., Wang, K., Huang, J., Xu, Z., Yuan, Q., Liu, L., Wang, Z., Miao, J., Wang, H., Wang, T., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2508949 · Cited by 44 · see citing works

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

Lu, Y., Yang, Y., Zhu, G., Zeng, H., Fan, Y., Guo, F., Xu, D., Wang, B., Chen, D., & Ge, G. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83026 · Cited by 41 · see citing works

Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities

Elsebaie, H. A., El-Moselhy, T. F., El-Bastawissy, E. A., Elberembally, K. M., Badi, R. M., Elkaeed, E. B., Shaldam, M. A., Eldehna, W. M., & Tawfik, H. O. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107101 · Cited by 41 · see citing works

Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)

Kang, Z., Shen, L., Li, Y., Song, J., Peng, Y., & Chen, Y. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110447 · Cited by 39 · see citing works

The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment

Zhu, M., Li, S., Cao, X., Rashid, K., & Liu, T. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.011 · Cited by 38 · see citing works

Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4

Cai, M., Ma, F., Hu, C., Li, H., Cao, F., Li, Y., Dong, J., & Qin, J. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117352 · Cited by 38 · see citing works

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization

Sun, Y., Dong, Y., Liu, X., Zhang, Y., Bai, H., Duan, J., Tian, Z., Xiang, Y., Wang, J., & Wang, Z. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104200 · Cited by 36 · see citing works

IL-13–induced STAT3-dependent signaling networks regulate esophageal epithelial proliferation in eosinophilic esophagitis

Marella, S., Sharma, A., Ganesan, V., Ferrer-Torres, D., Krempski, J. W., Idelman, G., Clark, S., Nasiri, Z., Vanoni, S., Zeng, C., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.07.021 · Cited by 35 · see citing works

Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment

He, P., Bian, A., Miao, Y., Jin, W., Chen, H., He, J., Li, L., Sun, Y., Ye, J., Liu, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01554 · Cited by 34 · see citing works

Identification of marine natural product Pretrichodermamide B as a STAT3 inhibitor for efficient anticancer therapy

Li, R., Zhou, Y., Zhang, X., Yang, L., Liu, J., Wightman, S. M., Lv, L., Liu, Z., Wang, C., & Zhao, C. (2023) · Marine Life Science & Technology · doi:10.1007/s42995-022-00162-x · Cited by 34 · see citing works

Epithelial–mesenchymal transition to mitigate age-related progression in lung cancer

Thapa, R., Gupta, S., Gupta, G., Bhat, A. A., Smriti, Smriti, Ali, H., Singh, S. K., Dua, K., & Kashyap, M. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102576 · Cited by 34 · see citing works

Endothelial Stat3 activation promotes osteoarthritis development

Li, J., Zhang, W.-C., Liu, X., Li, G., Gu, Y., Zhang, K., Shen, F., Wu, X., Jiang, Y., Zhang, Q., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13518 · Cited by 33 · see citing works

Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer

Guan, X., Yang, J., Wang, W., Zhao, B., Hu, S., Yu, D., Yuan, L., Shi, Y., Xu, J., Dong, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106703 · Cited by 33 · see citing works

Synthesis of 1,3,4-Thiadiazole Derivatives and Their Anticancer Evaluation

Stecoza, C. E., Nițulescu, G. M., Draghici, C. C., Căproiu, M. T., Hanganu, A., Olaru, O. T., Mihai, D. P., Bostan, M., & Mihaila, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417476 · Cited by 32 · see citing works

Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression

Xu, R., Zhou, H., Bai, L., McEachern, D., Wu, D., Acharyya, R. K., Wang, M., Tošović, J., Yang, C., Chinnaswamy, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01946 · Cited by 31 · see citing works

Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?

Berkley, K., Zalejski, J., & Sharma, A. K. (2025) · Cancers · doi:10.3390/cancers17050755 · Cited by 31 · see citing works

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Wu, D., Sun, Q., Tang, H., Xiao, H., Luo, J., Ouyang, L., & Sun, Q. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101176 · Cited by 30 · see citing works

Acacetin Inhibits the Growth of STAT3-Activated DU145 Prostate Cancer Cells by Directly Binding to Signal Transducer and Activator of Transcription 3 (STAT3)

Sun, Y., Lee, Y.-J., Choi, J., Kim, N. D., Han, D. C., & Kwon, B. (2021) · Molecules · doi:10.3390/molecules26206204 · Cited by 29 · see citing works

Small-Molecule PROTACs for Cancer Immunotherapy

Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 29 · see citing works

Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment

He, P., Miao, Y., Sun, Y., Bian, A., Jin, W., Chen, H., Ye, J., He, J., Peng, Y., Gu, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00413 · Cited by 29 · see citing works

Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations

Rafiq, H., Hu, J., Hakami, M. A., Hazazi, A., Alamri, M. A., Alkhatabi, H. A., Mahmood, A., Alotaibi, B. S., Wadood, A., & Huang, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-46193-x · Cited by 29 · see citing works

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects

Cheng, D., Ge, K., Yao, X., Wang, B., Chen, R., Zhao, W., Fang, C., & Ji, M. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1209947 · Cited by 28 · see citing works

A Network Pharmacology Prediction and Molecular Docking-Based Strategy to Explore the Potential Pharmacological Mechanism of Astragalus membranaceus for Glioma

Feng, Y., Zhu, P., Wu, D., & Deng, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216306 · Cited by 28 · see citing works

SNORA28 Promotes Proliferation and Radioresistance in Colorectal Cancer Cells through the STAT3 Pathway by Increasing H3K9 Acetylation in the LIFR Promoter

Liu, X., Zhang, H., Fan, Y., Cai, D., Lei, R., Wang, Q., Li, Y., Shen, L., Gu, Y., Zhang, Q., et al. (2024) · Advanced Science · doi:10.1002/advs.202405332 · Cited by 27 · see citing works

Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation

Shao, M., Zhang, X., Sun, J., Dong, H., Han, X., Yang, Q., Chen, R., Shen, L., Xu, L., Wang, L., et al. (2025) · Exploration · doi:10.1002/exp.70000 · Cited by 26 · see citing works

Research progress of STAT3-based dual inhibitors for cancer therapy

Yang, X.-J., Xu, L., Yang, L., & Xu, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117382 · Cited by 23 · see citing works

SHF Acts as a Novel Tumor Suppressor in Glioblastoma Multiforme by Disrupting STAT3 Dimerization

Wang, J., Huang, Z., Ji, L., Chen, C., Wan, Q., Xin, Y., Pu, Z., Li, K., Jiao, J., Yin, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202200169 · Cited by 22 · see citing works

Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells

Wang, X., Zhao, Y., Li, X., Zhang, Q., He, J., Liu, Y., Li, M., & Luo, Z. Y. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c00201 · Cited by 22 · see citing works

Discovery of benzochalcone derivative as a potential antigastric cancer agent targeting signal transducer and activator of transcription 3 (STAT3)

Dong, J., Yang, J., Yu, W., Li, H., Cai, M., Xu, J., Xu, H., Shi, Y., Guan, X., Cheng, X., et al. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2100366 · Cited by 21 · see citing works

Targeting Stat3 with conditional knockout or PROTAC technology alleviates renal injury by Limiting pyroptosis

Ji, M.-L., Wang, J., Wu, M., Xu, C., Zhang, M., Chang, W.-B., Mao, X.-F., Li, C., Yu, J.-T., Zhang, D., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105739 · Cited by 20 · see citing works

Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer

Li, H., Wang, L., Cao, F., Yu, D., Yang, J., Yu, X., Dong, J., Qin, J., & Guan, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944455 · Cited by 19 · see citing works

Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors

Zhang, C., Yang, L., Yang, X., Gao, Q., Qu, Y. D., & Wu, L. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106541 · Cited by 19 · see citing works

The self-adjuvant heterocyclic lipid nanoparticles encapsulated with vaccine and STAT3 siRNA boost cancer immunotherapy through DLN-targeted and STING pathway

Liu, Z., Wang, Q., Feng, Y., Zhao, L., Dong, N., Zhang, Y. X., Yin, T., He, H., Tang, X., Gou, J., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.146474 · Cited by 19 · see citing works

Synthesis and evaluation of WK-X-34 derivatives as P-glycoprotein (P-gp/ABCB1) inhibitors for reversing multidrug resistance

Cao, F., Li, Y., Ma, F., Wu, Z., Li, Z., Chen, Z., Cheng, X., Qin, J., & Dong, J. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00612c · Cited by 19 · see citing works

Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy

Liu, Z., Liu, B., Feng, Y., Zhao, L., Wang, Q., He, H., Yin, T., Zhang, Y. X., Yang, L., Gou, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00392 · Cited by 19 · see citing works

Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)

Yang, R., Song, Y., Shakoor, K., Yi, W., Peng, C., & Liu, S. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12687 · Cited by 18 · see citing works

S3I-201 derivative incorporating naphthoquinone unit as effective STAT3 inhibitors: Design, synthesis and anti-gastric cancer evaluation

Li, H., Cai, M., Cao, F., Yu, D., Yang, J., Yu, W.-K., Chu, C., Guan, X., Qin, J., & Dong, J. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116941 · Cited by 18 · see citing works

Small Molecules as Anti‐inflammatory Agents: Molecular Mechanisms and Heterocycles as Inhibitors of Signaling Pathways

Basha, N. J. (2023) · ChemistrySelect · doi:10.1002/slct.202204723 · Cited by 18 · see citing works

Bipyridine Derivatives as NOP2/Sun RNA Methyltransferase 3 Inhibitors for the Treatment of Colorectal Cancer

Tang, Z., Zhang, N., Chen, S., Fang, J., Tang, X., Lou, Y., Jiang, Y., Ma, Y., Chen, X., Chen, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01323 · Cited by 18 · see citing works

Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety

Wang, K., Zhou, K., Zhong, N., Cao, L., Li, Z., Xiao, Y., Wang, G.-R., Huo, F., Zhou, J., Liu, B., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122635 · Cited by 17 · see citing works

Natural Product-Inspired Discovery of Naphthoquinone-Furo-Piperidine Derivatives as Novel STAT3 Inhibitors for the Treatment of Triple-Negative Breast Cancer

Fan, C., Lou, S., Shen, C., Liao, J., Ni, H., Chen, S., Zhu, Z., Hu, X., Xie, W., Zhao, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00872 · Cited by 17 · see citing works

Huaier Inhibits Gastric Cancer Growth and Hepatic Metastasis by Reducing Syntenin Expression and STAT3 Phosphorylation

Shi, Y., Li, Y., Xu, J., Xu, H., Wang, L., Huang, L., Xu, Z., & Cheng, X. (2022) · Journal of Oncology · doi:10.1155/2022/6065516 · Cited by 16 · see citing works

APC/C CDH1 ubiquitinates STAT3 in mitosis

Bhattacharjee, D., Kaveti, S., & Jain, N. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106333 · Cited by 15 · see citing works

The molecular effects underlying the pharmacological activities of daphnetin

Wei, Z., Wei, N., Su, L., & Gao, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1407010 · Cited by 16 · see citing works

FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

Li, J., Dai, P., Sun, J., Yu, W., Han, W., & Li, K. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14750 · Cited by 15 · see citing works

DDIAS, DNA damage-induced apoptosis suppressor, is a potential therapeutic target in cancer

Im, J., Kang, M., Kim, B., & Won, M. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00974-6 · Cited by 15 · see citing works

Structural Optimization of Marine Natural Product Pretrichodermamide B for the Treatment of Colon Cancer by Targeting the JAK/STAT3 Signaling Pathway

Zhou, Y., He, N., Liu, Q., Li, R., Yang, L., Kang, W., Zhang, X., Xu, X., Yao, G., Wang, P., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00278 · Cited by 15 · see citing works

20(S)-Ginsenoside Rh2 induces apoptosis and autophagy in melanoma cells via suppressing Src/STAT3 signaling

Li, J., Jiang, X., Zhang, Z., Chen, W., Peng, J.-J., Liu, B., Yung, K., & Zhu, P. (2024) · Journal of Ginseng Research · doi:10.1016/j.jgr.2024.07.002 · Cited by 15 · see citing works

The direct STAT3 inhibitor 6-ethoxydihydrosanguinarine exhibits anticancer activity in gastric cancer

Liu, X., Jin, X., Ou, H., Chen, Q., Wu, H. L., Zuo, C., Ren, Y., Fu, M., Zhang, T., Zhang, L., et al. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0027 · Cited by 15 · see citing works

Inonotsutriol E from Inonotus obliquus exhibits promising anti breast cancer activity via regulating the JAK2/STAT3 signaling pathway

Shan, P., Wang, C., Chen, H., Yu, J., & Zhang, H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106741 · Cited by 16 · see citing works

Novel inhibitors of STAT3: an updated patent review (2022–present)

Bao, K., Li, P., & Gao, D. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2494857 · Cited by 14 · see citing works

Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3

Deng, L., Mo, J., Zhang, Y., Peng, K., Li, H., Ouyang, S., Feng, Z., Fang, W., Wei, J., Rong, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00940 · Cited by 14 · see citing works

Sertindole, an Antipsychotic Drug, Curbs the STAT3/BCL-xL Axis to Elicit Human Bladder Cancer Cell Apoptosis In Vitro

Hsu, C., Yang, W.-T., Lin, J., Lu, C., Hu, K.-C., Lan, T., & Chang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411852 · Cited by 13 · see citing works

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system

Xie, H., & Zhang, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116168 · Cited by 14 · see citing works

Impact of STAT-signaling pathway on cancer-associated fibroblasts in colorectal cancer and its role in immunosuppression

Sánchez-Ramírez, D., Mendoza-Rodríguez, M., Alemán, O. R., Candanedo-González, F., Rodríguez‐Sosa, M., Montesinos, J. J., Salcedo, M., Brito-Toledo, I., Vaca‐Paniagua, F., & Terrazas, L. I. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.1705 · Cited by 14 · see citing works

E2F1-induced autocrine IL-6 inflammatory loop mediates cancer-immune crosstalk that predicts T cell phenotype switching and therapeutic responsiveness

Spitschak, A., Dhar, P., Singh, K. P., Casalegno‐Garduño, R., Gupta, S. K., Vera, J., Musella, L., Murr, N., Stoll, A., & Pützer, B. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1470368 · Cited by 14 · see citing works

Unraveling the role of STAT3 in Cancer Cachexia: pathogenic mechanisms and therapeutic opportunities

Lv, X., & Ding, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1608612 · Cited by 16 · see citing works

Unveiling the Power of Dark State Photocages: An Efficient Pathway to Triplet State Under Near‐Infrared Light Irradiation

Hu, Q. L., Du, J., Abedi, S. A. A., Liu, X., Long, S., Sun, W. C., Fan, J., & Peng, X. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202504670 · Cited by 13 · see citing works

Discovery of two biotin-PEG4‑diarylidenyl piperidone prodrugs as potent antitumor agents with good efficacy, limited toxicity, and low resistance

Liu, S.-Q., Mao, Z.-C., Xü, Y., Chen, X.-M., Wang, H., Wang, Q., Wei, J.-H., Huang, R.-Z., & Zhang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106323 · Cited by 13 · see citing works

Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy

Carelock, M. E., Master, R. P., Kim, M., Jin, Z., Wang, L. A., Maharjan, C. K., Hua, N., De, U., Kolb, R. H., Xiao, Y., et al. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad019 · Cited by 13 · see citing works

Dual-responsive PEG–lipid polyester nanoparticles for siRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment

Liu, Z., Zhao, L., Feng, Y., Wang, Q., Dong, N., Zhang, Y. X., Yin, T., He, H., Tang, X., Gou, J., et al. (2023) · Biomaterials Science · doi:10.1039/d3bm01265d · Cited by 13 · see citing works

Natural bioactive compounds and STAT3 against hepatocellular carcinoma: An update

Manoharan, S., Saha, S., Murugesan, K., Santhakumar, A., & Perumal, E. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122351 · Cited by 14 · see citing works

Research on the signaling pathways related to the intervention of traditional Chinese medicine in Parkinson's disease:A literature review

Jin, X., Dong, W., Chang, K., & Yan, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117850 · Cited by 13 · see citing works

Targeting tumor-associated macrophages in gastric cancer progression and therapy: insights from molecular mechanisms to therapeutic applications

Wan, C., Deng, J., Zhu, Y. T., Wan, L., Xu, L., Chen, Q., Zou, C., & Huang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549694 · Cited by 14 · see citing works

Investigating the Potential Therapeutic Targeting of the JAK-STAT Pathway in Cerebrovascular Diseases: Opportunities and Challenges

Wu, J., Wang, B., Shen, L.-P., Chen, Y.-L., Du, Z., Du, S., Lu, X.-J., & Zhao, X. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04834-4 · Cited by 12 · see citing works

Eupalinolide J Inhibits Cancer Metastasis by Promoting STAT3 Ubiquitin-Dependent Degradation

Hu, H., Bai, H., Huang, L., Yang, B., & Zhao, H. (2023) · Molecules · doi:10.3390/molecules28073143 · Cited by 12 · see citing works

Synthesis and Biological Evaluation of Novel 2-Amino-1,4-Naphthoquinone Amide-Oxime Derivatives as Potent IDO1/STAT3 Dual Inhibitors with Prospective Antitumor Effects

Huang, R.-Z., Liang, Q., Jing, X.-T., Wang, K., Zhang, H., Wang, H., Ma, X., Wei, J.-H., & Zhang, Y. (2023) · Molecules · doi:10.3390/molecules28166135 · Cited by 11 · see citing works

Sculponeatin A induces mitochondrial dysfunction in non‐small cell lung cancer through WWP2‐mediated degradation of mitochondrial STAT3

Wan, F., Chen, Q., Liu, X., Zhong, Y., Peng, W., Zhang, L. N., Zhan, X., Huang, Y., Zhang, C., Wang, J., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17460 · Cited by 11 · see citing works

Novel Mannich-Type Multicomponent Reactions: Discovery, Mechanism, and Application

Zhou, X., Lai, Z., Li, J., Fan, C., & Cui, S. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00338 · Cited by 11 · see citing works

Discovery of Juglone Derivatives as Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer

Zhang, Z., Liao, Y., Zhang, J., Li, Q., Feng, Y., & Yu, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01301 · Cited by 11 · see citing works

Structural optimization of Imidazo[1, 2-a]pyridine derivatives for the treatment of gastric cancer via STAT3 signaling pathway

Li, H., Ouyang, S., Zhang, Y., Peng, K., Fang, W., Liu, Z., Wang, C., Zhang, X., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114858 · Cited by 11 · see citing works

STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer

Dong, D., Zhou, Z., Zhu, M., Hou, Z.-Y., Chen, M., Gong, J., Zhao, X.-Y., Yan, A., Liang, H., & Yin, Y.-X. (2025) · Nature Communications · doi:10.1038/s41467-025-63083-0 · Cited by 10 · see citing works

Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)

Wang, F., Cao, X., Lin, G., Tian, P., & Gao, D. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2056013 · Cited by 10 · see citing works

Glucocorticoid Receptor-Targeted Nanoliposome for STAT3 Inhibition-Led Myeloid-Derived Suppressor Cell Modulation and Efficient Colon Cancer Treatment

Bhattacharyya, T., Das, P., Ansari, A., Mohan, A. A., Chandra, Y., Narayan, K. P., & Banerjee‬‬‬‬‬‬‬‬‬, R. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00002 · Cited by 10 · see citing works

Discovery of naphthoquinone-furo-piperidone derivatives as dual targeting agents of STAT3 and NQO1 for the treatment of breast cancer

Lou, S., Shen, C., Ni, H., Fan, C., Zhu, Z., Hu, X., Zhao, H., & Cui, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117377 · Cited by 9 · see citing works

The effects of STAT3 acetylation on the transcriptional activity and tumorigenesis

Yan, H., Tang, L., Zhu, Y., & Zhang, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117076 · Cited by 9 · see citing works

Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling in vitro

Meng, M., Tan, J., Chen, H., Shi, Z., Kwan, H. Y., & Su, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18488 · Cited by 10 · see citing works

Non-coding RNAs and exosomal ncRNAs in multiple myeloma: An emphasis on molecular pathways

Hashemi, M., Roshanzamir, S. M., Paskeh, M. D. A., Karimian, S. S., Mahdavi, M. S., Kheirabad, S. K., Naeemi, S., Taheriazam, A., Salimimoghadam, S., Entezari, M., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175380 · Cited by 9 · see citing works

The Janus kinase 1 is critical for pancreatic cancer initiation and progression

Shrestha, H., Rädler, P. D., Dennaoui, R., Wicker, M. N., Rajbhandari, N., Sun, Y., Peck, A. R., Vistisen, K. S., Triplett, A. A., Beydoun, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114202 · Cited by 8 · see citing works

PKN2 enhances the immunosuppressive activity of polymorphonuclear myeloid-derived suppressor cells in esophageal carcinoma by mediating fatty acid oxidation

Fu, X., Zhang, G., Hou, Z., Fu, T., & Cui, G. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01132-6 · Cited by 8 · see citing works

Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)

Kang, Z., Shen, L., Li, Y., Song, J., Peng, Y., & Chen, Y. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110447 · Cited by 39 · see citing works

Targeting the STAT3 pathway with STAT3 degraders

Wang, Z., Liao, X., He, H., Guo, X., & Chen, J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.07.003 · Cited by 46 · see citing works

Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives

Song, J., Wang, J., Tian, S., & Li, H. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220819093117 · Cited by 54 · see citing works

Small Molecule Inhibitors of STAT3 for Cancer Therapy

Zhao, M. L., Jiang, B., & Gao, F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796957284 · Cited by 82 · see citing works

Strategies and Approaches of Targeting STAT3 for Cancer Treatment

Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 348 · see citing works